First-in-Human attack on KRAS cancer mutation begins
NCT ID NCT04111458
Summary
This is the first study in humans testing a new drug, BI 1701963, designed to block a specific cancer-driving mutation called KRAS. It is being tested alone and combined with an existing drug, trametinib, in 71 adults with advanced solid tumors where previous treatments have failed. The main goals are to find safe dose levels and see if the treatments can shrink tumors.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMORS, KRAS MUTATION; SOS1 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Erasmus Medisch Centrum-ROTTERDAM-50697
Rotterdam, 3015 GD, Netherlands
-
Levine Cancer Institute
Charlotte, North Carolina, 28204, United States
-
Sarah Cannon Research Institute-Nashville-48456
Nashville, Tennessee, 37203, United States
-
The University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Universitair Medisch Centrum Utrecht
Utrecht, 3584 CX, Netherlands
-
Universitätsklinikum Frankfurt
Frankfurt am Main, 60590, Germany
-
Universitätsklinikum Köln (AöR)
Cologne, 50937, Germany
Conditions
Explore the condition pages connected to this study.